Palliative Care

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

ASH 2017, Multiple Myeloma, Palliative Care

Atlanta, GA—The largest-ever analysis of palliative care trends has found the use of palliative care services to be sporadic at best among patients with hematologic malignancies. According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied. [ Read More ]

Trajectory of Illness and Distress in Patients Undergoing Stem-Cell Transplantation

Chase Doyle

November 2016, Vol 7, No 10 - Palliative Care

San Francisco, CA—As a result of recent advances in therapy, indications for stem-cell transplant are expanding, along with the number of patients eligible for the procedure. However, the intense and cure-oriented nature of transplants can lead to various forms of distress in patients who undergo this treatment, said Christina K. Ullrich, MD, MPH, Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, at the 2016 Palliative Care in Oncology Symposium. [ Read More ]

Disparities in Rehospitalization Rates Among Patients with Advanced Cancer

Chase Doyle

November 2016, Vol 7, No 10 - Palliative Care

San Francisco, CA—In addition to being costly for public and private payers, hospital readmissions can lead to increased risk for complications, hospital-acquired infections, and psychological distress in patients with advanced cancer. Although preventing readmissions would improve patient outcomes and decrease healthcare costs, the underlying causes of rehospitalization are not completely understood, suggested Robin L. Whitney, RN, PhD, Betty Irene Moore School of Nursing, University of California, Davis, and colleagues in a poster presentation at the 2016 Palliative Care in Oncology Symposium. [ Read More ]

Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL

Phoebe Starr

June 2015, Vol 6, No 5 - Palliative Care

Chicago, IL—The combination of ibrutinib (Imbruvica) plus standard therapy with bendamustine (Treanda) and rituximab (Rituxan) significantly reduced the risk for disease progression or death by 80% compared with bendamustine plus rituximab alone in previously treated patients with chronic ­lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), according to lead investigator Asher A. Chanan-Khan, MD, Chair, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL. [ Read More ]

Early Initiation of Palliative Care Improves Survival in Patients with Advanced Cancer

Laura Morgan

June 2015, Vol 6, No 5 - Palliative Care

Palliative care offers symptom relief, comfort, and peaceful death to patients with advanced cancer. Historically, palliative care was provided to patients who were near death. Based on recent research, however, the American Society of Clinical Oncology now recommends combining palliative care with curative treatment early in the disease course. Nevertheless, an important question remains: How early in the disease trajectory should patients with advanced cancer begin receiving palliative care? [ Read More ]